KRAS and serous adenocarcinoma: GSEA pathway analysis of those 26 neoplasms demonstrated that the G2M checkpoint pathway, E2F transcription factors, and KRAS downstream signaling were upregulated compared to fusion-negative, low grade serous carcinomas of the ovary, fallopian tube, or peritoneum (Figure 1).